Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityNo recent work listed

Luming Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3217-7460; OpenAlex author ID A5101697641. Sources: OpenAlex.

Their work

Papers
21 (first author 1, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
66
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 3 papers · 2014: none · 2015: 2 papers · 2016: 3 papers · 2017: 1 paper · 2018: 3 papers · 2019: 4 papers · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 2 papers

Papers 21

  1. Qingyihuaji Formula promotes apoptosis and autophagy through inhibition of MAPK/ERK and PI3K/Akt/mTOR signaling pathway on pancreatic cancer in vivo and in vit… Co-author DOI 10.1016/j.jep.2023.116198↗
  2. M2 macrophage-derived exosomal miR-193b-3p promotes progression and glutamine uptake of pancreatic cancer by targeting TRIM62. Co-author DOI 10.1186/s13062-023-00356-y↗
  3. NUCB1 Suppresses Growth and Shows Additive Effects With Gemcitabine in Pancreatic Ductal Adenocarcinoma via the Unfolded Protein Response. Last author DOI 10.3389/fcell.2021.641836↗
  4. BaBao Dan Suppresses Tumor Growth of Pancreatic Cancer Through Modulating Transcriptional Reprogramming of Cancer-Related Genes. Last author DOI 10.3389/fonc.2020.584330↗
  5. ARHGAP4 regulates the cell migration and invasion of pancreatic cancer by the HDAC2/β-catenin signaling pathway. Co-author DOI 10.1093/carcin/bgz067↗
  6. Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer. Co-author DOI 10.1186/s12967-019-1782-x↗
  7. Long non-coding RNA LINC00346 promotes pancreatic cancer growth and gemcitabine resistance by sponging miR-188-3p to derepress BRD4 expression. Co-author DOI 10.1186/s13046-019-1055-9↗
  8. ARHGAP4 mediates the Warburg effect in pancreatic cancer through the mTOR and HIF-1α signaling pathways. Last author DOI 10.2147/ott.s207560↗
  9. Pretreatment values of bilirubin and albumin are not prognostic predictors in patients with advanced pancreatic cancer. Last author DOI 10.1002/cam4.1848↗
  10. Effects of baicalein on pancreatic cancer stem cells via modulation of sonic Hedgehog pathway. Last author DOI 10.1093/abbs/gmy045↗
  11. Natural Compound Methyl Protodioscin Suppresses Proliferation and Inhibits Glycolysis in Pancreatic Cancer. Co-author DOI 10.1155/2018/7343090↗
  12. Low serum miR-373 predicts poor prognosis in patients with pancreatic cancer. Co-author DOI 10.3233/cbm-170231↗
  13. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Co-author DOI 10.1002/cncr.30057↗
  14. Ski modulate the characteristics of pancreatic cancer stem cells via regulating sonic hedgehog signaling pathway. Last author DOI 10.1007/s13277-016-5461-8↗
  15. Cyr61-positive cancer stem-like cells enhances distal metastases of pancreatic cancer. Co-author DOI 10.18632/oncotarget.12248↗
  16. Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Co-author DOI 10.1007/s13277-015-3097-8↗
  17. Qingyihuaji Formula Inhibits Pancreatic Cancer and Prolongs Survival by Downregulating Hes-1 and Hey-1. Last author DOI 10.1155/2015/145016↗
  18. A binuclear complex constituted by diethyldithiocarbamate and copper(I) functions as a proteasome activity inhibitor in pancreatic cancer cultures and xenograf… First author DOI 10.1016/j.taap.2013.09.009↗
  19. MicroRNA 23b regulates autophagy associated with radioresistance of pancreatic cancer cells. Co-author DOI 10.1053/j.gastro.2013.07.048↗
  20. shRNA-mediated Slc38a1 silencing inhibits migration, but not invasiveness of human pancreatic cancer cells. Co-author DOI 10.3978/j.issn.1000-9604.2013.09.03↗
  21. Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations. Co-author DOI 10.1038/ng.1020↗

Closest collaborators

The 25 strongest of 66 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhiqiang Meng · 10 shared papers, 2013–2019 · strength 0.69
  2. Zhen Chen · 10 shared papers, 2013–2019 · strength 0.68
  3. Zhouyu Ning · 4 shared papers, 2017–2021 · strength 0.42
  4. Yongqiang Hua · 4 shared papers, 2017–2021 · strength 0.41
  5. Hao Chen · 5 shared papers, 2015–2019 · strength 0.37
  6. Weidong Shi · 4 shared papers, 2013–2021 · strength 0.36
  7. Lianyu Chen · 5 shared papers, 2013–2019 · strength 0.35
  8. Peng Wang · 5 shared papers, 2013–2018 · strength 0.35
  9. Libin Song · 3 shared papers, 2016–2023 · strength 0.35
  10. Yehua Shen · 4 shared papers, 2015–2019 · strength 0.33
  11. Huifeng Gao · 3 shared papers, 2013–2023 · strength 0.33
  12. Hao Hui Chen · 2 shared papers, 2016–2023 · strength 0.29
  13. Xiangyuan Chen · 3 shared papers, 2016–2020 · strength 0.28
  14. Chao Qu · 3 shared papers, 2016–2018 · strength 0.23
  15. Chenyue Zhang · 3 shared papers, 2016–2019 · strength 0.23
  16. Linjia Peng · 1 shared paper, 2023 · strength 0.22
  17. Ke Zhang · 1 shared paper, 2023 · strength 0.22
  18. Liping Zhuang · 3 shared papers, 2013–2019 · strength 0.20
  19. Changyu Li · 1 shared paper, 2023 · strength 0.18
  20. Xuming Ji · 1 shared paper, 2023 · strength 0.18
  21. Xiang Qian · 1 shared paper, 2023 · strength 0.18
  22. Hao Chen · 2 shared papers, 2018–2019 · strength 0.18
  23. Song Gao · 2 shared papers, 2016–2018 · strength 0.16
  24. Ye Li · 1 shared paper, 2021 · strength 0.15
  25. Ke Zhang · 1 shared paper, 2021 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.